Health
Antimicrobial Resistance
|
Antimicrobial resistance (AMR) is a complex issue of global concern with potentially dramatic health and economic consequences. The OECD provides countries with the evidence to implement effective and cost-effective One Health policies to tackle AMR, promote effective use of antimicrobials in human and animal health, strengthen infection prevention and control measures, and incentivise research and development in the antibiotic sector.
|
|
LATEST EVENT – HIGH-LEVEL ONE HEALTH MINISTERIAL CONFERENCE ON ANTIMICROBIAL RESISTANCE
|
|
High-Level One Health Ministerial Meeting On Antimicrobial Resistance, French Presidency of the EU Council The OECD, in collaboration with the European Centre for Disease Prevention and Control, the European Food Safety Authority and the European Medicines Agency, has produced a briefing note on antimicrobial resistance (AMR) in the European Union and European Economic Area. It presents trends in antibiotic consumption and AMR from a One Health perspective, and sets out policy options for national governments and the European Union.
|
Key documents on antimicrobial resistance
- Antimicrobial resistance in long-term care facilities, OECD Health Working Paper No. 136, February 2022
- Financial strategies targeting healthcare providers to promote the prudent use of antibiotics: a systematic review of the evidence, International Journal of Antimicrobial Agents, December 2021
- Impact of vaccination on carriage of and infection by antibiotic-resistant bacteria: a systematic review and meta-analysis, Clinical and Experimental Vaccine Research, May 2021
G7 WORK ON AMR
The G7 has consistently committed to tackling global health challenges, including the fight against infectious diseases, and positioned itself as a leading partner in reaching health-related Millennium Development Goals, by initiating and supporting many global instruments of response to threats posed by infectious diseases.
In 2022, the German Presidency of the G7 commissioned OECD and WHO a joint briefing paper on addressing the burden of infections and antimicrobial resistance associated with health care, with a focus on G7 Countries. Findings in the report assess the level of implementation of infection prevention and control policies both in G7 countries and globally to make a strong economic case for scaling up action.
- Read the full report: Addressing the burden of infections and antimicrobial resistance associated with health care – Focus on G7 countries (available on October 18, 14h00 CET)
In 2015, the OECD released a first report to support G7 action in the area of AMR:
- Read the full report: Antimicrobial Resistance in G7 Countries and Beyond - Economic Issues, Policies and Options for Action
- Policy Brief on Antimicrobial resistance in G7 countries and beyond
G20 WORK ON AMR
Read the note prepared for the G20 by OECD along with WHO, FAO and OIE, on potential strategies to tackle antimicrobial resistance (AMR) and ensure sustainable research and development (R&D) for new antibiotics. The note calls for action based on a coordinated and cross-sectoral approach under the ‘One Health’ framework, highlights the urgent need to address barriers to innovation and suggests policy and governance mechanisms to reactivate the antibiotic R&D pipeline.
In the Hamburg G20 declaration, leaders called for a new R&D Collaboration Hub and committed to further examine practical market incentive options, in collaboration with relevant experts including from the OECD and the WHO.
FURTHER READING
- Learn more about our work on Public Health
- Discover our work on Pharmaceuticals
- Health Policies
- Health Publications
CONTACT
For more information, please contact [email protected]
Follow us on Twitter @OECD_Social
Related Documents